Volume 2.24 | Jun 24

Mammary Cell News 2.24 June 24, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Proteomic and Transcriptomic Profiling Reveals a Link Between the PI3K Pathway and Lower Estrogen Receptor (ER) Levels and Activity in ER+ Breast Cancer
Researchers examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype. [Breast Cancer Res]

Watch Procedure Now  
Learn to Enumerate Mammospheres and Tumorspheres
Cultured in MammoCult®
by STEMCELL Technologies
 
 
WATCH PROCEDURE NOW STEMCELL Technologies Inc
 



SCIENCE NEWS

Molecular Discovery Suggests New Strategy to Fight Cancer Drug Resistance
Scientists have found a way to disable a common protein that often thwarts chemotherapy treatment of several major forms of cancer. [Press release from the Dana-Farber Cancer Institute discussing online prepublication in Nature Chemical Biology]

Clinical Trials Favorable for Novel Breast Cancer Detection Device
A novel imaging device is showing favorable results in an expanded clinical trial and could significantly reduce physicians’ reliance on breast biopsies. [Press release from the University of Connecticut discussing online prepublication in Radiology]

Gene Mutation Increases Thromboembolism Risk in Women Taking Tamoxifen
Women taking tamoxifen for early-stage breast cancer who developed blood clots were more likely to carry a gene mutation for clotting than women taking tamoxifen who did not develop blood clots. [Press release from ScienceDaily discussing online prepublication in the Journal of the National Cancer Institute]

Breast Cancer Prophylaxis
Although the recent FDA approval of Dendreon Corp.’s Provenge therapeutic vaccine for prostate cancer finally has cemented immunotherapy’s place in the cancer armamentarium, the development of prophylactic cancer vaccines has lagged far behind. [SciBX Press Release]

DissociationEnzymes_645x110_v01



CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

A Mouse Knockout Library for Secreted and Transmembrane Proteins
Large collections of knockout organisms facilitate the elucidation of gene functions. Here, researchers used retroviral insertion or homologous recombination to disrupt 472 genes encoding secreted and membrane proteins in mice, providing a resource for studying a large fraction of this important class of drug target. [Nat Biotechnol]

The MCL-1 BH3 Helix is an Exclusive MCL-1 Inhibitor and Apoptosis Sensitizer
By screening a library of stabilized alpha-helix of BCL-2 domains, researchers determined that the MCL-1 BH3 helix is itself a potent and exclusive MCL-1 inhibitor. [Nat Chem Biol]

Interference with Sin3 Function Induces Epigenetic Reprogramming and Differentiation in Breast Cancer Cells
Here, researchers show that in both human and mouse breast cancer cells, the targeted disruption of Sin3 function by introduction of a Sin3 interaction domain (SID) decoy that interferes with paired amphipathic alpha-helices binding to SID-containing partner proteins reverted the silencing of genes involved in cell growth and differentiation. [Proc Natl Acad Sci U S A]

Notch1-Induced Mammary Tumor Development is Cyclin D1-Dependent and Correlates with Expansion of Pre-Malignant Multipotent Duct-Limited Progenitors
In young transgenic mice, expressing intracellular activated Notch1 [N1(IC)] in mammary cells, researchers found that CD24(+) CD29(high) progenitor cells had enhanced survival, and were expanded through a cyclin D1-dependent pathway. [Oncogene]

Deletion of p53 in Human Mammary Epithelial Cells Causes Chromosomal Instability and Altered Therapeutic Response
To evaluate the biological and clinical relevance of p53 loss, human somatic cell gene targeting was used to delete the TP53 gene in the non-tumorigenic epithelial cell line, MCF-10A. [Oncogene]

Molecular Subtypes of Breast Cancer are Associated with Characteristic DNA Methylation Patterns
Researchers analysed methylation status of 807 cancer-related genes in 189 fresh frozen primary breast tumours and four normal breast tissue samples using an array-based methylation assay. [Breast Cancer Res]

Cooperative Signaling Between Wnt1 and Integrin-Linked Kinase Induces Accelerated Breast Tumor Development
In order to investigate the potential interaction between Wnt and integrin-linked kinase (ILK) proteins during mammary tumor formation and progression, researchers have established a transgenic mouse model which expresses both Wnt and ILK in mammary epithelial cells. [Breast Cancer Res]

Placental Growth Factor (PlGF) Enhances Breast Cancer Cell Motility by Mobilising ERK1/2 Phosphorylation and Cytoskeletal Rearrangement
The purpose of this study was to determine the intracellular effects of PlGF and the inhibiting peptide, BP-1. [Br J Cancer]

CLINICAL RESEARCH

Use of Bisphosphonates and Risk of Postmenopausal Breast Cancer
The use of bisphosphonates for longer than 1 year was associated with a 28% relative reduction in the risk of postmenopausal breast cancer. Tumors developing under bisphosphonates treatment tended to have a favorable prognostic factors profile. [J Clin Oncol]

Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer
Among women taking adjuvant tamoxifen for early-stage breast cancer, those who had a thromboembolic event (TE) were nearly five times more likely to carry a Factor V Leiden mutation than those who did not have a TE. [J Natl Cancer Inst]



INDUSTRY NEWS

Breast Cancer Reconstruction Using Cell-Enriched Fat Grafts Shows Continued High Rates of Physician and Patient Satisfaction at 12 Months
Interim results from a breast reconstruction trial show stem and regenerative cell-enriched fat grafting resulted in a high sustained rate of physician and patient satisfaction and persistent improvements in overall outcomes of the procedure at six and twelve months. [Cytori Therapeutics, Inc. Press Release]

Kevetrin Demonstrates Significant Results in the Treatment of Multi-Drug Resistant Cancer Cells
Cellceutix Corporation announce that they have concluded more pre-clinical cell studies for Kevetrin, their flagship compound for the treatment of multi-drug resistant strains of lung, breast and colon cancers. [The Wall Street Journal]

Supreme Court Denies Wyeth’s Request For New Trial In Hormone Replacement Therapy Case
The Supreme Court denied Wyeth Pharmaceuticals’ request for a completely new trial of a lawsuit that claimed the drugmaker’s hormone replacement therapy drugs led to the plaintiff’s breast cancer. [Medical News Today]



POLICY NEWS

Hospital Clínic de Barcelona Obtained the First Accreditation for Cell Therapy Research
The certification, awarded for the first time in Catalonia, allows the Hospital Clínic de Barcelona to produce drugs in gene therapy, cell therapy and tissue engineering. [Spanish Medicines Agency, Spain]

New Videos Reveal How NIH Identifies the Most Promising Research Applications
The National Institutes of Health’s Center for Scientific Review released a new video to show new applicants and others how NIH assesses over 80,000 grant applications each year to help find those with the most merit. [National Institutes of Health, United States]

NIH and Wellcome Trust Announce Partnership to Support Genomic, Population-Based Studies in Africa
The National Institutes of Health (NIH) and the Wellcome Trust announced a partnership with African researchers to conduct genetic and environmental studies in Africa of common, non-communicable disorders, such as heart disease and cancer, as well as communicable diseases, such as malaria. [National Institutes of Health, United States]

Publication of New Enforcement Strategy
A new enforcement strategy has been published by the Inspection, Enforcement and Standards Division. [Medicines and Healthcare Products Regulatory Agency, United Kingdom]

Drugs Designated as Orphan Drugs [Therapeutic Goods Administration, Australia]

Therapeutic Goods Committee (TGC) (Updated) [Therapeutic Goods Administration, Australia]



EVENTS

The 21st Meeting of the European Association for Cancer Research (EACR)
June 26-29, 2010
Oslo, Norway

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

2nd International Conference on Cellular and Molecular Bioengineering (ICCMB2)
August 2-4, 2010
Singapore City, Singapore

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

15th Congress of the European Society of Surgical Oncology (ESSO)
September 15-17, 2010
Bordeaux, France

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

International Symposium on Breast Cancer Prevention: Nutrition, Communications, Public Policy
October 18-19, 2010
West Lafayette, United States

6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom


JOB OPPORTUNITIES

Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Visit our events page  to stay up to date with the latest events in the cell, gene and immunotherapy community.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!



Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us